Trial Profile
Does Dapagliflozin limit the progression of Echocardiographically-Assessed left Ventricular dysfunction in Diabetes Mellitus? (The LEAVE-DM trial).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LEAVE-DM
- 22 Sep 2021 Planned End Date changed from 15 Oct 2023 to 29 Feb 2024.
- 22 Sep 2021 Planned initiation date changed from 1 Mar 2020 to 12 Nov 2020.
- 05 Mar 2020 Planned initiation date changed from 15 Oct 2019 to 1 Mar 2020.